Research Analysts Offer Predictions for TARS Q1 Earnings

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a report released on Tuesday, February 25th. William Blair analyst L. Hanbury-Brown anticipates that the company will post earnings per share of ($0.06) for the quarter. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. William Blair also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at $0.32 EPS, Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.80 EPS and FY2026 earnings at $1.62 EPS.

A number of other research firms have also recently commented on TARS. HC Wainwright reissued a “buy” rating and set a $73.00 price target on shares of Tarsus Pharmaceuticals in a report on Wednesday. Guggenheim reissued a “buy” rating and issued a $78.00 price target (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research note on Friday, November 15th. Barclays reduced their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Oppenheimer raised their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $61.33.

Tarsus Pharmaceuticals Stock Up 3.1 %

Shares of TARS stock opened at $42.56 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The company’s fifty day moving average price is $51.31 and its 200-day moving average price is $43.00. The company has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.17 and a beta of 1.01.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.08. The company had revenue of $66.41 million during the quarter, compared to analyst estimates of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TARS. Creative Planning bought a new stake in Tarsus Pharmaceuticals during the third quarter worth approximately $362,000. China Universal Asset Management Co. Ltd. increased its position in shares of Tarsus Pharmaceuticals by 64.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,317 shares of the company’s stock valued at $241,000 after purchasing an additional 2,879 shares during the last quarter. Emerald Mutual Fund Advisers Trust bought a new stake in Tarsus Pharmaceuticals in the third quarter worth $3,608,000. Harbor Capital Advisors Inc. boosted its stake in Tarsus Pharmaceuticals by 57.5% during the third quarter. Harbor Capital Advisors Inc. now owns 18,105 shares of the company’s stock worth $595,000 after buying an additional 6,612 shares during the period. Finally, Emerald Advisers LLC bought a new position in Tarsus Pharmaceuticals during the third quarter valued at $4,812,000. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.